These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 2790193)

  • 1. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission.
    Adler A; Chervenick PA; Whiteside TL; Lotzová E; Herberman RB
    Blood; 1988 Mar; 71(3):709-16. PubMed ID: 3257887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Davis R; Ragab AH
    Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
    Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
    Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low molecular weight B-cell growth factor and recombinant interleukin-2 are together able to generate cytotoxic T lymphocytes with LAK activity from the bone marrow cells of children with acute lymphoblastic leukemia.
    Zhou MX; Findley HW; Ragab AH
    Blood; 1989 Sep; 74(4):1355-9. PubMed ID: 2788465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant interleukin-2-activated intracavitary lymphocytes: phenotypic characteristics and effector function.
    Umiel T; Monselise J; Klein T; Rakovsky E; Fenig E; Lurie H; Adler A
    J Biol Response Mod; 1989 Aug; 8(4):409-21. PubMed ID: 2787838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity.
    Anderson PM; Ochoa AC; Ramsay NK; Hasz D; Weisdorf D
    Blood; 1992 Oct; 80(7):1846-53. PubMed ID: 1391948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
    Archimbaud E; Bailly M; Doré JF
    Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
    Alderson MR; Sassenfeld HM; Widmer MB
    J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA; Szer J; Boyd RL
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphokine-activated killer cytotoxicity and lymphocyte subpopulations in patients with acute leukemia.
    Parrado A; Casares S; Rodríguez-Fernández JM
    Leuk Res; 1994 Nov; 18(11):815-22. PubMed ID: 7526078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.